Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Triple X syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44294   clinical trials with a EudraCT protocol, of which   7351   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    65 result(s) found for: Triple X syndrome. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2020-005200-19 Sponsor Protocol Number: I-CONIC Start Date*: 2022-05-09
    Sponsor Name:Västra Götalandsregionen/Onkologiska kliniken
    Full Title: Use of Imatinib to convert triple negative breast cancer into ER-positive breast cancer - "I-CONIC"
    Medical condition: Early Triple Negative Breast Cancer planned for surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004384-39 Sponsor Protocol Number: ABCSG-45 Start Date*: 2018-12-18
    Sponsor Name:Austrian Breast & Colorectal Cancer Study Group (ABCSG)
    Full Title: A prospective, open, randomized, phase II study of carboplatin/olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive ...
    Medical condition: Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003998-17 Sponsor Protocol Number: ONCOGHdC2015-01 Start Date*: 2017-02-16
    Sponsor Name:Grand Hôpital de Charleroi
    Full Title: A phase Ib/II study of Durvalumab (MEDI4736) combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)
    Medical condition: patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003693-33 Sponsor Protocol Number: CDX011-04 Start Date*: 2016-01-18
    Sponsor Name:Celldex Therapeutics, Inc.
    Full Title: A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer
    Medical condition: Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) AT (Prematurely Ended) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002264-41 Sponsor Protocol Number: P160932J Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Etude randomisée multicentrique évaluant l’efficacité et la tolérance de l’infliximab comparativement au Cyclophosphamide dans les formes sévères de maladie de Behçet " Multicenter, randomized, pro...
    Medical condition: Induction Therapy with Anti-TNF vs Cyclophosphamide in severe Behçet disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000017240 10004212 Behcet's disease LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024152-29 Sponsor Protocol Number: Start Date*: 2011-09-02
    Sponsor Name:University Hospital of Tübingen
    Full Title: Canakinumab for Behçet`s Disease Resistant to Standard Treatment (CanBeDisT)
    Medical condition: Behçet`s Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021428 - Immune system disorders 10004213 Behcet's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006083-45 Sponsor Protocol Number: CBKM120ZES02T/SOLTI-1103 Start Date*: 2012-03-20
    Sponsor Name:SOLTI (Grupo Español de Estudio, Tratamiento y Otras Estrategias Experimentales en Tumores Sólidos)
    Full Title: A phase II trial of BKM120 (a PI3K inhibitor) in patients with triple negative metastatic breast cancer
    Medical condition: triple negative metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-000189-45 Sponsor Protocol Number: Start Date*: 2018-03-26
    Sponsor Name:University of Padova
    Full Title: Adjuvant treatment for high-risk triple negative breast cancer patients with the anti-pd-l1 antibody Avelumab: A phase III randomized trial
    Medical condition: High risk triple negative (ER negative, PR negative, HER2 negative) breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004796-23 Sponsor Protocol Number: REP0114 Start Date*: 2015-07-06
    Sponsor Name:Dompé Farmaceutici s.p.a.
    Full Title: A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Can...
    Medical condition: Metastatic triple negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) CZ (Completed) IT (Completed) ES (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-000113-20 Sponsor Protocol Number: ABI-007-MBC-001 Start Date*: 2013-07-23
    Sponsor Name:Abraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation
    Full Title: A PHASE 2/3, MULTI-CENTER, OPEN-LABEL, RANDOMIZED STUDY OF WEEKLY nab®-PACLITAXEL IN COMBINATION WITH GEMCITABINE OR CARBOPLATIN, COMPARED TO GEMCITABINE/CARBOPLATIN, AS FIRST LINE TREATMENT IN SUB...
    Medical condition: ER, PgR, and HER2 negative (triple negative) metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004872 10006289 Benign and malignant breast neoplasms HLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Prematurely Ended) ES (Completed) DE (Prematurely Ended) GB (Prematurely Ended) IT (Completed) PT (Prematurely Ended) GR (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003906-26 Sponsor Protocol Number: ZEN003694-004 Start Date*: 2019-08-22
    Sponsor Name:Zenith Epigenetics Ltd.
    Full Title: A Phase 2 Study of ZEN003694 in Combination with Talazoparib in Patients with Triple-Negative Breast Cancer
    Medical condition: Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10071115 Node-negative breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002361-22 Sponsor Protocol Number: D5336C00001 Start Date*: 2017-12-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatm...
    Medical condition: Triple negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) ES (Ongoing) PL (Trial now transitioned) BE (Completed) FR (Completed) IE (Completed) NL (Completed) PT (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001128-11 Sponsor Protocol Number: BO20289 Start Date*: 2007-12-14
    Sponsor Name:F. Hoffmann-La Roche Ltd, Pharmaceuticals Divison, PDR
    Full Title: An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer.
    Medical condition: Early primary invasive adenocarcinoma of the breast (triple negative and/or basel-like phenotype)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006291 Breast neoplasms malignant and unspecified (incl nipple) HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) AT (Completed) NL (Completed) BE (Completed) CZ (Completed) GR (Completed) FI (Completed) DE (Completed) IT (Completed) ES (Completed) PT (Completed) SE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-004358-32 Sponsor Protocol Number: IJB–TNBC–1–RHEA Start Date*: 2015-05-07
    Sponsor Name:Institut Jules Bordet
    Full Title: Biomarker Research Study for PF-03084014 in cHEmoresistant triple negative breast cAncer - “RHEA” study
    Medical condition: patients with chemoresistant, triple-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001484-23 Sponsor Protocol Number: Triple-B Start Date*: 2013-05-24
    Sponsor Name:BOOG Study Center
    Full Title: Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumaB as first-line treatment in advanced triple negative Breast cancer
    Medical condition: Metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002286-30 Sponsor Protocol Number: A8641020 Start Date*: 2014-12-12
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: PHASE 2 STUDY OF SINGLE-AGENT PF 03084014 IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORS
    Medical condition: ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORS
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended) IT (Completed) BE (Prematurely Ended) ES (Completed) DE (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003093-13 Sponsor Protocol Number: BREAKFAST Start Date*: 2020-01-14
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Targeting triple negative BREAst cancer metabolism with a combination of chemotherapy and a diet mimicking FASTing plus/minus metformin in the preoperative setting: the BREAKFAST trial
    Medical condition: Targeting triple negative BREAst cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10025541 Malignant breast neoplasm LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002108-25 Sponsor Protocol Number: CC-10004-BCT-002 Start Date*: 2015-06-17
    Sponsor Name:Amgen Inc.
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY, FOLLOWED BY AN ACTIVE-TREATMENT PHASE TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE...
    Medical condition: SUBJECTS WITH ACTIVE BEHÇET’S DISEASE
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10004212 Behcet's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-001651-40 Sponsor Protocol Number: Phaon1 Start Date*: 2020-11-13
    Sponsor Name:palleos healthcare GmbH
    Full Title: An adaptive randomized neoadjuvant two arm trial in triple-negative breast cancer comparing a mono Atezolizumab window followed by a Atezolizumab - CTX therapy with Atezolizumab – CTX therapy (neoM...
    Medical condition: ER negative, PR negative and HER2 negative (triple negative) breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006437-40 Sponsor Protocol Number: TMC114HIV3006 Start Date*: 2007-02-05
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A randomised, controlled, opel-label trial to compare the efficacy, safety and tolerability of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination ...
    Medical condition: HIV-1
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020161 HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) HU (Completed) DK (Completed) DE (Completed) PT (Completed) ES (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA